Meritage Starts Study of Inflammatory Disease
Luke Timmerman1/22/09
Meritage Pharma, a San Diego-based drug developer, said today it has started a mid-stage clinical trial of an experimental drug for an inflammatory condition of the esophagus, called eosinophilic esophagitis. The trial will enroll 80 children and young adults on three different doses of the Meritage drug or a placebo. We profiled this company’s technology in detail back in December.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
